Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Humpe

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Molecular Cancer Therapeutics|October 7, 2025
Development of aGD2-SIRPα fusion antibodies targeting neuroblastoma and the innate immune checkpoint receptor CD47Fabian Schuurmans, Anja Wittner, Renske J E van den Bijgaart, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Antibodies (Basel, Switzerland)|November 20, 2020
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-EngineeringSophia Roßkopf, Klara Marie Eichholz, Dorothee Winterberg, et al.
Journal of Hematology & Oncology|September 28, 2021
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cellsSiret Tahk, Binje Vick, Björn Hiller, et al.
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Cancer Science|May 31, 2021
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactionsNiklas Baumann, Thies Rösner, J H Marco Jansen, et al.
Frontiers in Immunology|November 15, 2023
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cellsSebastian Lutz, Katja Klausz, Anca-Maria Albici, et al.
Nature Methods|December 24, 2021
Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4<sup>+</sup> T cells allows complex functional analysesManuel Albanese, Adrian Ruhle, Jennifer Mittermaier, et al.
Biological Chemistry|October 30, 2021
Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigenChristian Kellner, Sebastian Lutz, Hans-Heinrich Oberg, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Molecular Cancer Therapeutics|October 7, 2025
Development of aGD2-SIRPα fusion antibodies targeting neuroblastoma and the innate immune checkpoint receptor CD47Fabian Schuurmans, Anja Wittner, Renske J E van den Bijgaart, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Antibodies (Basel, Switzerland)|November 20, 2020
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-EngineeringSophia Roßkopf, Klara Marie Eichholz, Dorothee Winterberg, et al.
Journal of Hematology & Oncology|September 28, 2021
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cellsSiret Tahk, Binje Vick, Björn Hiller, et al.
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Cancer Science|May 31, 2021
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactionsNiklas Baumann, Thies Rösner, J H Marco Jansen, et al.
Frontiers in Immunology|November 15, 2023
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cellsSebastian Lutz, Katja Klausz, Anca-Maria Albici, et al.
Nature Methods|December 24, 2021
Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4<sup>+</sup> T cells allows complex functional analysesManuel Albanese, Adrian Ruhle, Jennifer Mittermaier, et al.
Biological Chemistry|October 30, 2021
Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigenChristian Kellner, Sebastian Lutz, Hans-Heinrich Oberg, et al.
Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.
Pageof 6